Suppr超能文献

遗传性和散发性胰腺导管腺癌:遗传学和影像学的最新进展。

Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging.

机构信息

Departments of Diagnostic Radiology (A.C.M., A.K.H., S.Y., S.R.P.) and Pathology (N.S.R.), The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Unit 1473, Houston, TX 77030-4009; Department of Radiology, University of Texas at San Antonio, San Antonio, Tex (V.S.K.); and Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, Pa (A.K.D.).

出版信息

Radiol Imaging Cancer. 2020 Mar 13;2(2):e190020. doi: 10.1148/rycan.2020190020. eCollection 2020 Mar.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a genetically heterogeneous, biologically aggressive malignancy with a uniformly poor prognosis. While most pancreatic cancers arise sporadically, a small subset of PDACs develop in patients with hereditary and familial predisposition. Detailed studies of the rare hereditary syndromes have led to identification of specific genetic abnormalities that contribute to malignancy. For example, germline mutations involving , , , and mismatch repair genes predispose patients to PDAC. While patients with Lynch syndrome develop a rare "medullary" variant of adenocarcinoma, intraductal papillary mucinous tumors are observed in patients with McCune-Albright syndrome. It is now well established that PDACs originate via a multistep progression from microscopic and macroscopic precursors due to cumulative genetic abnormalities. Improved knowledge of tumor genetics and oncologic pathways has contributed to a better understanding of tumor biology with attendant implications on diagnosis, management, and prognosis. In this article, the genetic landscape of PDAC and its precursors will be described, the hereditary syndromes that predispose to PDAC will be reviewed, and the current role of imaging in screening and staging assessment, as well as the potential role of molecular tumor-targeted imaging for evaluation of patients with PDAC and its precursors, will be discussed. Abdomen/GI, Genetic Defects, Oncology, Pancreas © RSNA, 2020.

摘要

胰腺导管腺癌(PDAC)是一种遗传异质性强、生物学侵袭性强、预后普遍较差的恶性肿瘤。虽然大多数胰腺癌是散发性的,但一小部分 PDAC 发生在具有遗传和家族易感性的患者中。对罕见遗传性综合征的详细研究导致了特定遗传异常的鉴定,这些异常导致了恶性肿瘤的发生。例如,涉及、、和错配修复基因的种系突变使患者易患 PDAC。虽然林奇综合征患者会发生罕见的腺癌“髓样”变体,但 McCune-Albright 综合征患者会出现导管内乳头状黏液性肿瘤。现在已经明确,PDAC 是由于累积遗传异常,通过从小的和大的前体多步进展而来的。对肿瘤遗传学和肿瘤发生途径的认识的提高有助于更好地了解肿瘤生物学,并对诊断、治疗和预后产生影响。本文将描述 PDAC 及其前体的遗传特征,综述易患 PDAC 的遗传性综合征,并讨论影像学在筛查和分期评估中的当前作用,以及分子肿瘤靶向成像在评估 PDAC 及其前体患者中的潜在作用。腹部/胃肠,遗传缺陷,肿瘤学,胰腺。©RSNA,2020。

相似文献

1
Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging.
Radiol Imaging Cancer. 2020 Mar 13;2(2):e190020. doi: 10.1148/rycan.2020190020. eCollection 2020 Mar.
2
Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
J Surg Oncol. 2019 May;119(6):777-783. doi: 10.1002/jso.25376. Epub 2019 Jan 12.
4
Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance.
Gastroenterology. 2018 Sep;155(3):740-751.e2. doi: 10.1053/j.gastro.2018.05.035. Epub 2018 May 24.
6
PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
Eur J Cancer. 2015 Sep;51(14):1911-7. doi: 10.1016/j.ejca.2015.07.004. Epub 2015 Jul 23.
7
High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer.
Cancer Prev Res (Phila). 2018 Nov;11(11):679-686. doi: 10.1158/1940-6207.CAPR-18-0014. Epub 2018 Oct 1.
8
Pancreatic intraductal papillary mucinous neoplasm in a patient with Lynch syndrome.
World J Gastroenterol. 2015 Mar 7;21(9):2820-5. doi: 10.3748/wjg.v21.i9.2820.
10
Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms.
J Med Ultrason (2001). 2019 Oct;46(4):435-439. doi: 10.1007/s10396-019-00949-z. Epub 2019 May 8.

引用本文的文献

3
6
9
A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer.
J Cancer Immunol (Wilmington). 2024;6(4):148-153. doi: 10.33696/cancerimmunol.6.095.
10
Sex-Related Differences in Pancreatic Ductal Adenocarcinoma Progression and Response to Therapy.
Int J Mol Sci. 2024 Nov 26;25(23):12669. doi: 10.3390/ijms252312669.

本文引用的文献

1
Drugging an undruggable pocket on KRAS.
Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):15823-15829. doi: 10.1073/pnas.1904529116. Epub 2019 Jul 22.
2
Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
J Surg Oncol. 2019 May;119(6):777-783. doi: 10.1002/jso.25376. Epub 2019 Jan 12.
3
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861. doi: 10.3748/wjg.v24.i43.4846.
4
Precursor Lesions of Pancreatic Cancer.
Oncol Res Treat. 2018;41(10):603-610. doi: 10.1159/000493554. Epub 2018 Sep 28.
5
Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis.
Gene. 2018 Dec 30;679:328-334. doi: 10.1016/j.gene.2018.09.029. Epub 2018 Sep 15.
6
Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer.
Pancreas. 2018 Jul;47(6):675-689. doi: 10.1097/MPA.0000000000001075.
7
European evidence-based guidelines on pancreatic cystic neoplasms.
Gut. 2018 May;67(5):789-804. doi: 10.1136/gutjnl-2018-316027. Epub 2018 Mar 24.
8
Pancreatic cancer screening.
Abdom Radiol (NY). 2018 Feb;43(2):264-272. doi: 10.1007/s00261-017-1308-z.
9
The regulation of β-catenin activity and function in cancer: therapeutic opportunities.
Oncotarget. 2017 May 16;8(20):33972-33989. doi: 10.18632/oncotarget.15687.
10
Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.
Int J Mol Sci. 2017 Apr 6;18(4):779. doi: 10.3390/ijms18040779.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验